Agent Capital
Venture capitalActively deployingWaltham · Pre-Seed–Late Stage · 22 people tracked
Also known as AGENT CAPITAL, LLC
Investment thesis
Agent Capital is a healthcare-focused venture firm backing novel and differentiated therapeutics aimed at unmet patient needs. It invests across all stages of development and collaborates with scientists, entrepreneurs, and co-investors to advance the next generation of healthcare innovations. The firm takes a balanced investment approach grounded in an understanding of biopharma pipeline pressures, proactively guiding biotech companies toward key milestones and exits. Its typical areas of focus include rare diseases, oncology, neurology, and immunology, and it is willing to invest regardless of stage or investment type.
Source: firm website, verified Aug 3, 2026.
Team · 22 people
from the firm's website
What they invest in
from 27 of 71 portfolio companiesBiotech ×27Healthtech ×12Medical Devices ×7AI & Machine Learning ×3Deep Tech ×3Digital Health ×3Advanced Manufacturing ×1Longevity ×1
HQs:United States×20
Investments · 71 tracked
founders shown can be your intro pathBedford, US
Board seatBruce Peacock· per SEC Form D · $37.5M raise · filed Mar 2019
Boston, US
Board seatGeeta Vemuri· per SEC Form D · $22M raise · filed Jul 2019
BiotechWarrington, US
Mary B. Templeton(Executive Officer)Craig E. Fraser(Executive Officer, Director)Lawrence A. Weinstein(Executive Officer)Kathryn Cole(Executive Officer)Marvin E. Rosenthale(Director)Joseph M. Mahady(Director)
Board seatBruce Peacock· per SEC Form D · $26.4M raise · filed Dec 2019
BiotechWaltham, US
JOSEPH FARMER(Executive Officer)PATRICK GERALD ENRIGHT(Director)HONGBO LU(Director)TOMAS KISELAK(Director)LEON O. MOULDER, JR.(Director)JOHN JACOB ORLOFF(Director)
Board seatJohn Orloff· per SEC Form D
Entrada Therapeutics develops intracellular therapeutics using its EEV Platform to target previously inaccessible disease-causing targets within cells, with a pipeline spanning retinal, neuromuscular, and metabolic diseases including Duchenne muscular dystrophy.
BiotechHealthtechMedical DevicesBoston, US
Carole Nuechterlein(Director)Natarajan Sethuraman(Executive Officer)Kush M. Parmar(Director)inTodd Foley(Director)Peter Kim(Director)Nerissa Kreher(Executive Officer)
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)Stuart Lawson(Director)Charles Roberts(Director)Gabriel Otte(Director)
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.
BiotechSouth San Francisco, US
Kevin Raidy(Director)Suzanne Bruhn(Director)Johannes Hull(Executive Officer)John Curnutte(Director)Hoyoung Huh(Director)Neil Exter(Director)
Precision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform.
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)TODD MELBY(Executive Officer)BEN AUSPITZ(Director)Jeff Smith(Co-founder)
BiotechPhiladelphia, US
Susan B Dillon(Executive Officer, Director)Karyn O'Neil(Executive Officer, Director)Mark V. Laurenzi(Executive Officer)Elizabeth Anderson(Director)Bruce Peacock(Director)
Board seatBruce Peacock· per SEC Form D · $5M raise · filed Jan 2020
Luxembourg
Joanna Shields(Director, Executive Officer)Jean Raby(Director)Olivier Brandicourt(Director)Nick Keher(Executive Officer)Susan Liautaud(Director)Ivan Griffin(Executive Officer)
Board seatJohn Orloff· per SEC Form D · filed Sep 2022
Board seatGeeta Vemuri· per SEC Form D
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)Margarita Chavez(Director)Eran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)
Board seatBruce Peacock· per SEC Form D · $3.9M raise · filed Apr 2018
BiotechMt. Arlington, US
Abbie Celniker(Director)David Guyer(Director)Paul Chaney(Executive Officer, Director)Bruce Peacock(Director)
Board seatBruce Peacock· per SEC Form D · $47.3M raise · filed Apr 2019
Biotech
James A. Geraghty(Director)Joanne T. Beck(Director)Bobby Gaspar(Executive Officer, Director)Marc Dunoyer(Director)Steven M. Altschuler(Director)Frank E. Thomas(Executive Officer)
Orchestrates the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
āshibio is a clinical-stage biotech developing therapies for bone and connective tissue disorders, with clinical programs targeting heterotopic ossification conditions (including fibrodysplasia ossificans progressiva) and autosomal dominant osteopetrosis type 2.
BiotechHealthtechBurlingame, US
BiotechPhiladelpia, US
Joshua Brandt(Director)Errik Anderson(Executive Officer, Director)Ross Leimberg(Executive Officer, Director)Geeta Vemuri(Executive Officer, Director)
Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS.
BiotechDeep TechHealthtech
Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)
Dragonfly develops immunotherapies, including B and T cell depleters and immune engagers, targeting autoimmune and inflammatory diseases, oncology, fibrosis, and neuro-inflammation.
BiotechHealthtech
Foresight Diagnostics develops ultra-sensitive diagnostic tests using genomics and bioinformatics to detect minimal residual disease in cancer patients, serving clinical and biopharma partners in oncology drug development and patient care.
AI & Machine LearningBiotechMedical Devices<UNKNOWN>
A biotechnology company developing a ground-breaking platform of therapeutics called GEM-DIMERs.
BiotechBurlingame, US
Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)Daniel J. Capon(Director)Malcolm L. Gefter(Director)William D. Unger(Director)Samuel Saks(Director)
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Laura Brass(Director)Amanda Wagner(Executive Officer)Kai Wucherpfennig(Director)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Nu-Tek BioSciences manufactures 100% animal-free specialty yeast extracts, peptones, and hydrolysates used in cell culture media and biologic production.
Advanced ManufacturingBiotechNew Materials
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Orbus Therapeutics develops and commercializes therapies for patients with rare diseases that have few effective treatments, currently working on eflornithine in North America and Europe.
BiotechHealthtech
Palvella Therapeutics is a biotechnology company developing topical treatments for rare genetic skin diseases that lack approved therapies, based on its QTORIN drug delivery platform.
BiotechHealthtechWayne, US
BiotechSan Diego, US
Helge Zieler(Director, Executive Officer)
BoardJ. Todd Mitchell(Director)Matthew Korenberg(Director)Matthew Reber(Director)Wes Kaupinen(Director)
Developing SKY-0515 for Huntington's Disease; running the global pivotal FALCON-HD clinical trial.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Agent Capital invest at?
- Agent Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Agent Capital focus on?
- Agent Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Agent Capital located?
- Agent Capital is headquartered in Waltham, US.
- Does Agent Capital lead rounds?
- Yes, Agent Capital leads investment rounds.
Images
Co-investors · 12
Longwood Fund is a Boston-based venture firm focused on discovering and building science-based companies, with a team spanning doctors, scientists, entrepreneurs, and investors.
OUP (Osage University Partners) is a venture capital firm that backs science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
MPM BioImpact is a life sciences investment firm that creates, builds, and invests in biotechnology and healthcare companies developing transformative medicines, spanning both private company creation and public market investing.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Bain Capital Life Sciences, founded in 2016, invests in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on companies addressing unmet medical needs and driving medical innovation.
M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Trinity Ventures is an early-stage venture capital firm that invests in mission-driven entrepreneurs and their companies.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Cofounders Capital is a North Carolina-based venture firm that leads seed-stage investments in B2B software companies across the southeastern United States.
AbbVie Ventures is the corporate venture capital arm of biopharmaceutical company AbbVie, investing in early-stage companies in oncology, immunology, and neurodegenerative diseases that complement the parent company's research and development pipeline.
Firms observed investing alongside Agent Capital, from public investor directories. Shared companies are the overlap with Agent Capital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
SV Health Investors is a healthcare-focused private equity and venture capital investment platform managing specialized and diversified funds across biotechnology, healthcare growth equity, and medtech.